Use of prescription opioids with abuse-deterrent technology to address opioid abuse

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1589-1598

  Michna, Edward ^a   Kirson, Noam Y ^b   Shei, Amie ^b   Birnbaum, Howard G ^b   Ben Joseph, Rami ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ANALYSIS GROUP   (United States)

^c PURDUE PHARMA L P   (United States)

Author keywords

Drug abuse; Opioid related disorders; Opioids; Pain

Indexed keywords

OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT;

ABUSE DETERRENT TECHNOLOGY; ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG FORMULATION; DRUG UTILIZATION; HEALTH CARE ACCESS; HUMAN; ICD-9-CM; OPIATE ADDICTION; PRESCRIPTION; TECHNOLOGY; ADMINISTRATION AND DOSAGE; ADOLESCENT; CHRONIC PAIN; COMPLICATION; DELAYED RELEASE FORMULATION; EVALUATION STUDY; FEMALE; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT ATTITUDE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; THERAPEUTIC USE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; OXYMORPHONE; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES; YOUNG ADULT;

EID: 84904906740     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.915803     Document Type: Article

References (15)

1. Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control. CDC. Prescription painkiller overdoses. November 2011. Available at: http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact- PrescriptionPainkillerOD.pdf [Last accessed November 2013]
2. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. Available at: http://www.samhsa.gov/data/NSDUH/2012Summ NatFindDetTables/ NationalFindings/NSDUHresults2012.pdf [Last accessed September 2013]
3. Office of National Drug Control Policy. Epidemic: Responding to America's prescription drug abuse crisis. 2011. Available at: http://www.whitehouse. gov/sites/default/files/ondcp/policy-and-research/rxabuseplan.pdf [Last accessed March 2014]
4. U.S. Food and Drug Administration. FDA introduces new safety measures for extended-release and long-acting opioid medications. 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 310870.htm [Last accessed January 2013]
5. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. Morb Mortal Wkly Rep 2011;60:1487-92
6. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
7. U.S. Food and Drug Administration. Guidance for Industry. Abuse-Deterrent Opioids - Evaluation and Labeling. Draft Guidance. 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM334743.pdf [Last accessed February 2013]
8. Woodcock J. A difficult balance - pain management, drug safety, and the FDA. N Engl J Med 2009;361:2105-7
9. FDA approves abuse-deterrent labeling for reformulated OxyContin. Silver Spring, MD: U.S. Food and Drug Administration, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 348252.htm [Last accessed 16 August 2013]
10. Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014: published online 16 February 2014, doi:10.1016/j.drugalcdep.2014. 02.006
11. FDA Statement: Original Opana ER Relisting Determination. Silver Spring, MD: U.S. Food and Drug Administration, 2013. Available at: http://www.fda.gov/ Drugs/DrugSafety/ucm351357.htm [Last accessed 4 February 2014]
12. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351-8
13. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187-9
14. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
15. White AG, Birnbaum HG, Rothman DB, et al. Development of a budgetimpact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009;7:61-70